Athanor Capital’s Arcturus Therapeutics ARCT Stock Holding History

Athanor Capital’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-4,791	Closed	-$224K	–	540
2020 Q2	$224K	Buy	+4,791	New	+$165K	0.01%	476

Other funds holding ARCT

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Athanor Capital's ARCT Position: Q3 2020 in Review

Athanor Capital sold out of Arcturus Therapeutics (ARCT) in Q3 2020, closing a stake of 4,791 shares — an estimated $224K sold.

Athanor Capital first reported a position in ARCT in Q2 2020 and held it in 1 quarter. The position peaked at $224K in Q2 2020. 127 funds tracked by Wall St. Rank hold ARCT as of Q3 2020.

Athanor Capital reported no remaining Arcturus Therapeutics position as of Q3 2020 after selling out during the quarter.
Athanor Capital sold 4,791 Arcturus Therapeutics shares in Q3 2020, an estimated $224K.
Athanor Capital first reported a position in Arcturus Therapeutics in Q2 2020 and held it in 1 quarter.
Athanor Capital's Arcturus Therapeutics position peaked at $224K in Q2 2020.
127 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2020.

Based on Athanor Capital's 13F filing for Q3 2020, filed 16 Nov 2020.